First Wave BioPharma raises ~$1.1M in registered direct offering priced at $2.95/share

GridAI Technologies Corp.

Gross proceeds expected ~$1.1M; net proceeds ~$0.9M after agent fees.
Offering includes 366,000 shares/pre-funded warrants at $2.95 and warrants for 732,000 shares at $2.70.
Warrants are immediately exercisable, 6-year term, exercise price $2.70.
Proceeds to be used for working capital and general corporate purposes.
Closing expected on or about May 14, 2024, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GridAI Technologies Corp. entered into Purchase Agreement with certain purchasers valued at approximately $0.9 million (effective 2024-05-10).

Action: entry
Agreement: equity purchase
Counterparty: certain purchasers
Value: approximately $0.9 million
Effective: 2024-05-10

Exact text from the filing

On May 10, 2024, First Wave BioPharma, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GridAI Technologies Corp. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2024-05-10).

Action: entry
Agreement: underwriting
Counterparty: Roth Capital Partners, LLC
Effective: 2024-05-10

Exact text from the filing

On May 10, 2024, First Wave BioPharma, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)

View on SEC.gov

Browse all material agreements →

GridAI Technologies Corp. filing history →

Source: SEC EDGAR

accession 0001104659-24-060689

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.